Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
'Huel,' A British Plant-Based Nutrition Company Backed By Idris Elba, Sells for $1.15 Billion
16+ hour, 2+ min ago (283+ words) The actor and his wife invested in the company years before Danone agreed to acquire it for nearly $1.15 billion. Idris Elba’s latest business win is less about Hollywood and more about getting in early. The actor and his wife, Sabrina…...
Novartis investors turn spotlight on M&A after trial setbacks
1+ day, 11+ hour ago (418+ words) By Bhanvi Satija, Oliver Hirt and Marleen Kaesebier LONDON/ZURICH, Sept 11 (Reuters) - Novartis investors are set to step up scrutiny of the Swiss group's dealmaking strategy after setbacks to drugs...
Big UK Pharma is Trying to Curtail Your Ability to Complain About its Behaviour | Principia Scientific, Intl.
19+ hour, 25+ min ago (568+ words) Written by Dr Alan Black on September 12, 2026. Posted in Current News If you are a member of the British public and you want to complain about something a pharmaceutical company has done, said or written, you effectively have one option....
AstraZeneca’s breast cancer pill fails in late-stage trial
1+ day, 20+ hour ago (301+ words) Sept 11 (Reuters) – AstraZeneca’s breast cancer pill failed to meet the main goal of improving progression-free survival in a late-stage trial, the company said on Friday, a week after the treatment received U.S. approval. U.S.-listed shares of AstraZeneca…...
AstraZeneca’s breast cancer pill fails in a late-stage trial
1+ day, 18+ hour ago (281+ words) AstraZeneca’s breast cancer pill failed to meet the main goal of improving progression-free survival in a late-stage trial, the company said on Friday, a week after the treatment received US approval. US-listed shares of AstraZeneca fell 3% in aftermarket trading. The…...
Novartis: More Pain on the Way?
1+ day, 6+ hour ago (100+ words) Can it get any worse for Novartis’ U.S. stock? The Swiss company said Tuesday that del-desiran, part of a recent acquisition, reached the end of the line in a trial for a rare neuromuscular disease. The drugmaker’s U.S.-listed…...
AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss — Executive ‘Disappointed,’ Reiterates Breast Cancer Focus
1+ day, 23+ hour ago (424+ words) Etcamah is a once-daily pill that breaks down the estrogen receptor many breast cancers use to grow and is already approved for a narrower group of breast cancer patients. The setback lands on a pipeline already under scrutiny. Shares of…...
Olema drops after hours on AstraZeneca Etcamah data
1+ day, 6+ hour ago (15+ words) Olema stock drops after AstraZeneca’s SERD/CERAN phase 3 setback for Etcamah. Read more here....
Pharma wins a battle over the cost of wastewater treatment in Europe
1+ day, 6+ hour ago (180+ words) In a boost for the pharmaceutical industry, a European Union Advocate General recommended annulling part of a directive that requires drug and cosmetics manufacturers to finance at least 80% of the costs of wastewater treatment. The directive, which revised an earlier…...
AstraZeneca Trips On Unexpected Failure In Breast Cancer
1+ day, 8+ hour ago (138+ words) AstraZeneca stock toppled in late trades Friday after the company's experimental breast cancer treatment failed to pass muster. The post AstraZeneca Stock Trips On Unexpected Failure In Breast Cancer appeared first on Investor's Business Daily. AstraZeneca (AZN) stock toppled in…...